Single Shot Eases MS Symptoms in 16-Patient Trial

Imagine getting a single shot that teaches your own immune system to stop attacking itself.

That's exactly what happened for 16 patients with multiple sclerosis and similar autoimmune conditions in a groundbreaking clinical trial. Instead of the weeks-long, expensive process of removing and engineering immune cells in a lab, researchers delivered the treatment directly into patients' bodies with one injection.

The results were remarkable. Symptoms improved across all participants, and follow-up tests showed their immune systems had essentially hit a reset button. The treatment stopped the friendly fire that causes these devastating diseases, with effects lasting over six months.

CAR T cell therapy has already proven itself against blood cancers that were once untreatable. But the traditional method is a logistical puzzle that takes weeks to complete and costs hundreds of thousands of dollars. Patients must undergo toxic chemotherapy to clear out their existing immune cells before receiving the specially engineered ones.

The new approach changes everything. Researchers led by Dai-Shi Tian used a virus to carry genetic instructions straight to T cells inside the body, transforming them into disease-fighting machines on the spot. These newly programmed cells hunted down rogue B cells that produce autoantibodies attacking healthy tissue.

Multiple sclerosis gradually destroys the protective coating around nerve fibers, scrambling the electrical signals controlling our bodies. It typically strikes young and middle-aged adults, and there's currently no cure. This trial offers genuine hope where little existed before.

The treatment caused few severe side effects, addressing one of the biggest concerns about creating CAR T cells inside the body rather than in controlled lab conditions. Previous attempts at shortcuts have led to serious complications, including a recent trial halt by Novartis after three deaths.

The Ripple Effect

Beyond helping these 16 patients, this proof-of-concept opens doors for millions of people worldwide suffering from autoimmune disorders. If the approach works in larger trials, CAR T therapy could transform from an exclusive treatment available only at specialized centers into something more like a regular drug.

The time savings alone could be lifesaving for patients who don't have weeks to wait. The potential cost reduction could bring hope to people currently priced out of treatment entirely.

Georg Schett at University Hospital Erlangen, who reviewed the research, called it "a clear go signal" for larger studies. Over 1,500 CAR T clinical trials are now registered worldwide, testing the therapy against solid tumors and various autoimmune conditions like lupus.

The study was small and had no control group, so scientists need more evidence before celebrating a cure. But the door to simpler, safer, more accessible treatment just opened wider than ever before.